Compare NetApp Inc. (NTAP) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Novo Nordisk A/S — how do they compare? NetApp Inc. trades at $237.19 (market cap $45.38B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.6× NetApp Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 56 Days and Novo Nordisk A/S for 116 Days on average.
| NTAP | NVO | |
|---|---|---|
Market Cap | $45.38B | $165.31B |
Volume | 2,264,311 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $235.84 | $63.98 |
52-Week Low | $94.11 | $35.29 |
Typical Hold Time | 56 Days | 116 Days |
Enterprise Value | $44.34B | $179.56B |
Dividend Yield | 0.9% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $237.15, up 0.56% today, with strong technical momentum as the stock approaches resistance near $239. The company demonstrates robust fundamentals with a 70.63% gross margin and consistent earnings beats, including Q2 2026 EPS of $2.58 beating expectations by 21.7%. Recent AI infrastructure partnerships with Oracle and Supermicro position NTAP for growth in enterprise data storage markets.
While valuation metrics appear elevated with a P/E of 32.63, the company's AI-driven growth strategy and strong profitability support upside potential. Key risks include competitive pressures in cloud storage and potential margin compression. Analyst consensus remains mixed with 38% buy ratings but a $219.30 price target below current levels, suggesting cautious optimism.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
